

Supplemental Digital Content 5. Description of patients who died during the study

	Nivolumab dose	Duration of sepsis (at administration)	Primary site of infection	Cause of death	Co-morbidities
Patient 1	480 mg	1 day	Lung	Multi-organ failure	<ul style="list-style-type: none"> • Acute renal failure • Atrial fibrillation • Prostatic hyperplasia • Heart failure • Cerebral infarction • Chronic kidney disease • Diabetes mellitus • Hypertension • Pneumonia • Itching
Patient 2	960 mg	3 days	Lung	Pneumonia (Not an AE)	<ul style="list-style-type: none"> • Asthma • Chronic kidney disease • Chronic obstructive • Pulmonary disease • Diabetes • Hyperlipidemia • Hypertension • Hyperuricemia • Insomnia
Patient 3	960 mg	1 day	Skin/ SoftTissue	Exacerbation of primary disease (Not an AE)	<ul style="list-style-type: none"> • Cerebral infarction • Hyperlipidemia • Hypertension • Oral floor carcinoma • Pulmonary metastasis
Patient 4	960 mg	2 days	Lung	Pneumonia (Not an AE) Multi-organ failure (Not an AE)	<ul style="list-style-type: none"> • Atrial fibrillation • Albumin decreased • Creatine kinase increased • Coarse crackles • Dry skin • Hemoglobin decreased • Bleeding tendency • Intraoral ulcer • Pancreatic enzyme increased • Severe pneumonia

AE, adverse event